Jefferies Group LLC Bei Gene, Ltd. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $1.46 Million - $2.08 Million	12,016 Added 301.61%	16,000 $1.97 Million
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $304,125 - $391,822	-2,668 Reduced 40.11%	3,984 $494,000
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $405,306 - $501,039	-3,300 Reduced 33.16%	6,652 $878,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $412,095 - $674,502	3,851 Added 63.12%	9,952 $1.4 Million
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $649,855 - $807,572	-4,258 Reduced 41.1%	6,101 $1.05 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $1.58 Million - $2.25 Million	10,359 New	10,359 $1.59 Million
Q1 2018 May 15, 2018	SELL	$97.41 - $177.22 $281,709 - $512,520	-2,892 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $230,203 - $331,799	2,892	2,892 $283,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.